QR kód

Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

BACKGROUND: Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects. METHODS: Randomized trials evaluated macitentan (SERAPHIN; NCT00660179) and selexipag (GRIP...

Celý popis

Uloženo v:
Hlavní autoři: Richard Channick, MD, Sarah Medrek, MD, Marion Delcroix, MD, Sean Gaine, MD, Pavel Jansa, MD, PhD, Irene Lang, MD, Vallerie McLaughlin, MD, Sanjay Mehta, MD, Tomas Pulido, MD, Bhagavatula Sastry, MD, Rogerio Souza, MD, PhD, Adam Torbicki, MD, Carol Zhao, MS, Paul Strachan, MD, Peter Agron, PhD, Joseph Yen, PhD, Olivier Sitbon, MD, PhD
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2025-02-01
Edice:JHLT Open
Témata:
Pulmonary arterial hypertension
SERAPHIN
GRIPHON
Selexipag
Macitentan
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2950133424001472
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky